The Great Margin Transfer: $11.7 Billion Flows From America's Largest Insurer to Healthcare Providers

In 2024, UnitedHealth Group sent $11.7 billion more to hospitals and doctors than it would have three years earlier—and nobody planned it.

The mechanics are straightforward: UnitedHealth's medical care ratio climbed from 85.5% to 88.9% in a single year, a 340 basis point deterioration. On $345 billion in insurance revenue, that arithmetic translates to nearly 3.4 cents of every premium dollar that once flowed to corporate shareholder value now flowing instead to claims payments. For hospital systems, that's the difference between sustaining margin pressure and achieving record earnings. For insurers, it's the difference between maintaining historical profitability and entering a margin crunch that hasn't been seen in a decade.

This isn't a phenomenon isolated to UnitedHealth. Across the managed care sector, average payer operating margins collapsed to just 0.5% in Q3 2025, down from 3% a year prior. Excluding Cigna—which has managed relative stability—the industry median operates at -1.4% margins. For the first time in the post-ACA era, major insurance carriers are running near breakeven or worse. Humana's medical loss ratio hit 90.4% in recent quarters, with Q4 spiking to 93.1%. CVS/Aetna reported a Q4 medical care ratio of 94.8%, the highest in its recent history. Molina stands at 91.7%. These aren't statistical outliers. They're the new industry floor.

Meanwhile, the beneficiaries of this margin transfer have experienced something approaching euphoria. HCA Healthcare reported revenue growth of 7.1% alongside net income growth of 17.8%—a disproportionate earnings expansion that reflects pure operating leverage flowing directly to the bottom line. Tenet Healthcare's adjusted EPS grew 41.2% while revenue expanded just 3.7%, an 11x earnings multiplier on revenue growth. For United Surgical Partners International—Tenet's ambulatory surgery center platform—margins now sit at 40%, a level previously considered theoretical for outpatient operations. HCA's net income grew 2.5 times faster than revenue. That gap tells you everything about where pricing power has settled in the healthcare value chain.

What Happened: The Simultaneous Unraveling of Managed Care Economics

The trigger was deceptively simple: Americans used healthcare services at unprecedented rates after the pandemic, and actuarial models built on 2019 utilization assumptions collapsed under the weight of 2024 reality. Medicare care activity surged to levels 2x pre-pandemic baseline, driven by pent-up demand, aging demographics, and chronic disease prevalence that hadn't declined during the pandemic hiatus. Outpatient volumes alone show forecast growth of 18% over the next decade—not 18% from today, but 18% compounded annually from the current elevated baseline. This wasn't a temporary surge. This was a structural upshift in demand that forced insurers to pay claims at volumes they'd priced for years earlier.

The second shock arrived via regulatory action. The Centers for Medicare & Medicaid Services proposed a 2027 Medicare Advantage rate increase of just 0.09%—effectively flat in nominal terms, deeply negative in real terms—despite industry expectations for 4–6% rate growth. For plans operating on historical 3% margins, a flat rate proposal while input costs rose mid-single digits created an immediate profitability collapse. Large insurers filed objections. The objections were largely ignored.

The third input was macroeconomic. The Inflation Reduction Act's drug pricing provisions began to reshape the economics of pharmaceutical benefits. Provider-side consolidation, despite antitrust scrutiny, continued to shift bargaining leverage away from payers and toward health systems. PwC projects an 8.5% medical cost trend for 2026—a figure that assumes no acceleration in utilization, purely input cost inflation. For insurers locked into flat or low-single-digit rate growth, an 8.5% cost trend creates an immediate 600–800 basis point squeeze.

What emerges from these three vectors is a kind of involuntary margin transfer. Insurers didn't choose to send $11.7 billion extra to providers. They lost the ability to avoid it. When regulatory rates don't move and claims costs accelerate and utilization stays elevated and input prices climb, the arithmetic allows only one outcome: margin contraction at the payer level and, consequently, margin expansion at the provider level.

Where the Money Landed: Provider Earnings in a Favorable Window

The hospital sector captured most of this flow. HCA's EBITDA margin now stands at approximately 20.6%, expanding rather than contracting despite input cost pressure. This expansion matters: it suggests that despite labor inflation, drug cost growth, and supply chain normalization at higher levels than 2019, major health systems are pricing and operating efficiently enough to let claims payments flow through to operating profit. At current scale, a 20.6% EBITDA margin on $80+ billion in annual revenue generates extraordinary free cash flow—capital that flows into facility expansion, technology investment, and shareholder returns.

Tenet's EBITDA margin expanded 200 basis points to 21.4%, even as the health system absorbed elevated labor costs and operating complexity. For Tenet's outpatient surgery centers—the highest-margin component of the portfolio—margins reached 40%. That's a structural feature of outpatient orthopedic and ophthalmologic surgery: minimal inpatient overhead, high acuity, predictable payers. When those payers shift from defensive pricing to effectively subsidized payment levels, the margin math becomes almost theoretical.

This creates a window—perhaps 12–18 months wide—during which provider profitability reaches levels that will eventually trigger pushback. McKinsey projects that provider EBITDA could decline approximately 2% by 2027–2028 as insurers begin to reprice aggressively. That's not a collapse. But it's the beginning of a reversion toward longer-term equilibrium margins. The Great Margin Transfer has a counterparty risk: the transferred margins are not permanent. They're the temporary consequence of a lagging adjustment cycle.

Why This Is Happening: The Utilization Surge Isn't Fading

The most critical input in this dynamic is utilization. Post-pandemic demand for healthcare—particularly among Medicare beneficiaries—never normalized downward. Medicare care activity runs at 2x pre-pandemic levels, a shift that actuarial models from 2019 simply did not forecast. The sources are multiple: deferred care from 2020–2021 creating a backlog of procedures, aging cohorts reaching Medicare eligibility with higher disease burden, obesity and metabolic disease becoming more prevalent, and chronic disease management becoming more aggressive. None of these reverse quickly.

Against this, insurers face a regulatory environment in which Medicare Advantage rate adjustments have decoupled entirely from medical trend. CMS's 2027 rate proposal of 0.09% growth stands in stark contrast to the 8.5% medical cost trend PwC projects. This gap is not temporary policy. It reflects a deliberate regulatory choice to cap insurer profitability in the Medicare Advantage space while allowing medical costs to rise. For health plans whose Medicare Advantage business represents 40–50% of enrolled lives, the implication is severe: either accept margin compression or implement aggressive cost containment measures that reduce access or network quality.

The political economy here is also relevant. Payer margins in the 0.5% range generate adverse headlines and regulatory scrutiny. Insurers have begun publicly signaling that they'll be "more selective" in participating in certain markets, narrowing networks, and raising premiums on non-Medicare populations. Industry observers expect premium increases of 8–10% for 2026 commercial business, with networks narrowing in lower-margin regions. This is the beginning of the pushback—not pricing power, but rather a tactical retreat to defend margins by reducing exposure to unprofitable segments.

What Comes Next: The Reversion is Structural, Not Cyclical

The Great Managed Care Reset—as some industry observers now call it—is fundamentally a lagging adjustment cycle. Insurers entered 2023–2024 with rate structures priced on utilization assumptions from 2019. They then experienced utilization that exceeded those assumptions by material amounts. Regulatory rates didn't adjust. Cost inflation accelerated. The result was a margin collapse that's severe and compressed but ultimately a function of timing misalignment, not structural insolvency.

What comes next is reversion. The reversion has multiple vectors. First, as rates adjust—whether through Medicare Advantage repricing, employer self-funded plan repricing, or commercial rate renewals—they'll incorporate the higher utilization baseline and elevated cost trend that 2024 data now makes undeniable. Expect average medical care ratios to stabilize in the 86–87% range over the next 18–24 months, recovering some margin but not to historical 84–85% levels. The utilization plateau is now structural. It's built into the base assumptions.

Second, insurers will pursue cost containment initiatives with renewed aggression. Network narrowing is already underway. Prior authorization for advanced imaging and specialty care is being tightened. Behavioral health networks are being contracted more aggressively. These measures have adverse PR consequences and clinical pushback, but for insurers operating at 0.5% margins, the alternative—sustained losses—is existential. The industry will choose narrowing and tension over red ink.

Third, provider margin expansion will peak and begin to contract as insurers reprice and as the utilization surge moderates from its 2024 peak. McKinsey's projection of a 2% EBITDA decline for providers by 2027–2028 assumes reputable, disciplined reductions in claims costs by major insurers. That may be optimistic. If insurers prove unable to control costs through network narrowing and utilization management, the margin squeeze extends further into the provider timeline, creating a more adversarial negotiation environment through 2027.

The window of maximum favorable conditions for providers—where utilization is elevated, costs are rising, and insurer repricing hasn't yet fully adjusted—is closing. It's not closed yet. But the timing has shifted from 2024 into 2025, and the endpoints are becoming visible. For hospital operators, this is the period to maximize capital deployment, fund growth initiatives, and optimize cost structures before the 2027–2028 margin compression cycle arrives. For insurers, it's the painful realization that the 3% margins of 2019–2022 are unlikely to return in a healthcare system where utilization has fundamentally reset to higher levels and regulatory rate discipline prevents full repricing.

The $11.7 billion that moved from UnitedHealth's margin line to provider balance sheets is not a permanent transfer. It's a visible artifact of a system in transition—one where actuarial assumptions collided with medical reality, regulatory decisions lagged cost inflation, and the resulting gap forced a temporary but substantial redistribution of profitability down the value chain. What happens next depends entirely on whether insurers can reprice faster than providers can consolidate their advantage. That race will define healthcare margins for the next three years.